Elahere
Elahere ingredients
| Active ingredient | Strength |
|---|---|
| Mirvetuximab Soravtansine | 5 mg/mL |
What Elahere is used for
The FDA lists the approved uses on the official label (below). In the EU, mirvetuximab soravtansine is approved as Elahere for:
Elahere as monotherapy is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Elahere
- Generic name
- Mirvetuximab soravtansine
- Made by
- ImmunoGen, Inc.
- Forms
- Injection, Solution
- Given
- Intravenous
- FDA approval
- Biologic licence (BLA) BLA761310
- On the US market since
- 2022
Official information
- Elahere prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Mirvetuximab soravtansine)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Elahere?
Elahere (Mirvetuximab soravtansine) is a cancer medicine made by ImmunoGen, Inc., approved by the US FDA.
What are the ingredients of Elahere?
Elahere contains Mirvetuximab Soravtansine (5 mg/mL).
Is Elahere approved in Europe?
The same active substance is approved in the EU as Elahere.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA